Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors—Synthetic Strategies and SAR Insights
Open accessThe DOI matches its Crossref record; 79 of the 81 references it cites were found in a registry or an index.
Abstract
Tropomyosin receptor kinases (Trks) are transmembrane receptor tyrosine kinases named TrkA, TrkB, and TrkC and encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. These kinases have attracted significant attention and represent a promising therapeutic target for solid tumor treatment due to their vital role in cellular signaling pathways. First-generation TRK inhibitors, i.e., Larotrectinib sulfate and Entrectinib, received clinical approval in 2018 and 2019, respectively. However, the use of these inhibitors was significantly limited because of the development of resistance due to mutations. Fortunately, the second-generation Trk inhibitor Repotrectinib (TPX-0005) was approved by the FDA in November 2023, while Selitrectinib (Loxo-195) has provided an effective solution to this issue. Another macrocycle-based analog, along with many other TRK inhibitors, is currently in clinical trials. Two of the three marketed drugs for NTRK fusion cancers feature a pyrazolo[1,5-a] pyrimidine nucleus, prompting medicinal chemists to develop numerous novel pyrazolopyrimidine-based molecules to enhance clinical applications. This article focuses on a comprehensive review of chronological synthetic developments and the structure–activity relationships (SAR) of pyrazolo[1,5-a]pyrimidine derivatives as Trk inhibitors. This article will also provide comprehensive knowledge and future directions to the researchers working in the field of medicinal chemistry by facilitating the structural modification of pyrazolo [1,5-a]pyrimidine derivatives to synthesize more effective novel chemotherapeutics as TRK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic presentation of Trk receptors and their major signal transduction pathway [53,54].](https://figures.cochat.ai/paper-figures/d62543c727cc4739ad111a2b5b026089/pyrazolo-1-5-a-pyrimidine-as-a-prominent-framework-for-tropomyosin-receptor-figure-1.jpg)
![Figure 2 Development of NTRK fusion inhibitors consisting of a pyrazolo[1,5-a]pyrimidine moiety.](https://figures.cochat.ai/paper-figures/ef45e81708bc45d2b94fe8ebd4754ce3/pyrazolo-1-5-a-pyrimidine-as-a-prominent-framework-for-tropomyosin-receptor-figure-2.jpg)





















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sustained TrkB activation enhances survival and growth signaling, and Trk family receptors are established oncogenic drivers when aberrantly engaged [135,136,137].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophins: Roles in Neuronal Development and Function
Huang, E. J., & Reichardt, L. F. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.677 · Cited by 4,394 · cited 9×
“and colleagues (2011) synthesized a new series of macrocyclic pyrazolo[1,5-a]pyrimidine derivatives and evaluated their activity using the TrkA Elisa enzyme assay.”
BackgroundInfluentialThe Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485 · cited 1×
“…cancer, prostate cancer, large cell neuroendocrine tumors, pediatrics gliomas and astrocytomas, intrahepatic cholangiocarcinomas, gastrointestinal stromal tumors, gallbladder adenocarcinomas, pancreatic carcinomas, and many other cancers have been associated with oncogenic forms of NTRK [26–44].”
BackgroundKaplan, D. R., Martin-Zanca, D., & Parada, L. F. (1991) · Nature · doi:10.1038/350158a0 · Cited by 1,055 · cited 1×
“Mainly, nerve growth factor (NGF), neurotrophin-7, and neurotrophin-6 bind to TrkA, and activation of TrkA triggers various signaling pathways involved in cell survival, differentiation, and growth, particularly in neurons and neuroblastomas [5].”
BackgroundKlein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90628-c · Cited by 958 · cited 1×
“[6 ].”
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
Martin-Zanca, D., Hughes, S. H., & Barbacid, M. (1986) · Nature · doi:10.1038/319743a0 · Cited by 803
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642 · cited 2×
“This leads to the activation of multiple downstream signal transduction pathways, such as PI3K-AKT and RAS-MAPK, and regulates the nervous system and neuronal cell cycle, proliferation, apoptosis, survival, and differentiation [9–13].”
BackgroundNTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Amatu, A., Sartore-Bianchi, A., & Siena, S. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000023 · Cited by 601 · cited 1×
“However, in the pathophysiology of malignant cancer in humans, Trks can be seen to be active through NTRK gene fusions [13,14].”
BackgroundDrilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504 · cited 1×
“2023 while Selitrectinib (Loxo-195 macrocycle-based representative, along with many other inhibitors, is currently being in clinical trials [58–60].”
BackgroundOncogenes in solid human tumours
Pulciani, S., Santos, E., Lauver, A. V., Long, L. K., Aaronson, S. A., & Barbacid, M. (1982) · Nature · doi:10.1038/300539a0 · Cited by 478 · cited 1×
“Over 100 distinct NTRK fusion partners have been found in various malignancies to date, with the first NTRK fusion gene, TPM3-NTRK1, found in human colorectal carcinoma in 1982 [15,16].”
Background
Research works printed but not linked: 4
- Kakizawa S. Neurotrophin-3 Handbook of Hormones (Second Edition) Ando H. Ukena K. Nagata S. Academic Press San Diego, CA, USA 2021 483 485 978-0-12-820649-2
- Batool Z. Azfal A. Liaquat L. Sadir S. Nisar R. Inamullah A. Faiz Ghalib A.U. Haider S. Receptor Tyrosine Kinases (RTKs): From Biology to Pathophysiology Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders Mansour H.M. Khattab M.M. El-khatib A.S. Academic Press Cambridge, MA, USA 2023 117 185 978-0-443-18677-6
- Numakawa T. Odaka H. Chapter 3—Roles of Trk Receptors, Tyrosine Kinase Receptors for Neurotrophins, in the Developing CNS Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders Mansour H.M. Khattab M.M. El-khatib A.S. Academic Press Cambridge, MA, USA 2023 79 115 978-0-443-18677-6
- Rashad A.E. Abdelmegid M. Shamroukh A.H. Abdelmegeid F.M. The Chemistry of Pyrazolopyrimidines and Their Applications Org. Chem. Ind. J. 2014 10 224 250
Cited by
Iorkula, T. H., Osayawe, O. J.-K., Odogwu, D. A., Ganiyu, L. O., Faderin, E., Awoyemi, R. F., Akodu, B. O., Ifijen, I. H., Aworinde, O. R., Agyemang, P., et al. (2025) · RSC Advances · doi:10.1039/d4ra07556k · Cited by 75
Ahmed, A. A., Mekky, A. E. M., & Sanad, S. M. H. (2024) · Synthetic Communications · doi:10.1080/00397911.2024.2428653 · Cited by 15
Elgiushy, H. R., Soliman, M. E., El‐Khouly, M. E., Abouzid, K. A. M., & Hammad, S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108792 · Cited by 8
Nasehi, P., Omidkhah, N., & Ghodsi, R. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108950 · Cited by 7
Efremov, A. N., Mitrofanov, A. Y., & Beletskaya, I. P. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c01957 · Cited by 3
Metadata
- Authors
- Mahajan, A. T., Shivani, Datusalia, A. K., Coluccini, C., Coghi, P., & Chaudhary, S.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- China Medical University (TW)
- Macau University of Science and Technology (MO)
- Corresponding author
- Coluccini, Carmine
- Coghi, Paolo
- Chaudhary, Sandeep
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2024-07-29
- Volume
- 29
- Issue
- 15
- Pages
- 3560
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC11314189
- OpenAlex
- W4401080166
- Cited by
- 12
- References
- 81
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 1
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- NIPER-Raebareli (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
- Science and Engineering Research Board (SERB) (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
- Ministry of Science and Technology in Taiwan (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
- Macao Science and Technology University (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Characterization of Heterocyclic Compounds
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- Trk receptors, TRK inhibitors, pyrazolo[1,5-a]pyrimidines, structure-activity relationship, larotrectinib, entrectinib, repotrectinib, resistance mutations, synthetic strategies, tyrosine kinase inhibitors
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Pyrazoles, Pyrimidines, Structure-Activity Relationship, Receptor, trkC, Receptor, trkB, Receptor, trkA, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.